A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT03563716. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT03563716
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Placebo Drug
- Tiragolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2018
- Primary completion
- Jun 29, 2019
- Completion
- Nov 13, 2025
- Last update posted
- May 3, 2026
2018 – 2025
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - HAL | Tempe | Arizona | 85284 | — |
| SCRI Florida Cancer Specialists South | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists - NORTH - SCRI - PPDS | St. Petersburg | Florida | 33705 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| University of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Research Medical Center | Kansas City | Missouri | 64132 | — |
| SCRI Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Northwest Cancer Specialists - Vancouver | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03563716, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03563716 live on ClinicalTrials.gov.